PUBBLICAZIONI 2014
Iurlo A., Fracchiolla N., *Ferla V., Cassin R., Gottardi E., Beghini A., Gianelli U., Spinelli O., Cortelezzi A.
Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified.
J CLIN ONCOL 2014; 32(10): e37-e39.
________________________________________
Giordano R., Canesi M., Isalberti M., Isaias I.U., Montemurro T., Viganò M., Montelatici E., Boldrin V., Benti R., Cortelezzi A., Fracchiolla N., Lazzari L., Pezzoni G.
Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study.
J TRANSL MED 2014; 12(): 14-14.
________________________________________
Foà R., Del Giudice I., Cuneo A., Del Poeta G., Ciolli S., Di Raimondo F., Lauria F., Cencini E., Rigolin G.M., Cortelezzi A., Nobile F., Callea V., Brugiatelli M., Massaia M., Molica M., Trentin L., Rizzi R., Specchia G., Di Serio F., Orsucci L., Ambrosetti A., Montillo M., Zinzani P.L., Ferrara F., Morabito F., Mura M.A., Soriani S., Peragine N., Tavolaro S., Bonina S., Marinelli M., De Propris M.S., Starza I.D., Piciocchi A., Alietti A., Runggaldier E.J., Gamba E., Mauro F.R., Chiaretti S., Guarini A.
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.
AM J HEMATOL 2014; 89(5): 480-486.
________________________________________
Barcellini W., Imperiali F., Zaninoni A., Reda G., Consonni D., Fattizzo B., Lonati S., Nobili L., Zanella A., Cortelezzi A.
Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression.
LEUK LYMPHOMA 2014; 55(8): 1768-1773.
________________________________________
Visco C., Cortelezzi A., Moretta F., Falisi E., Maura F., Finotto S., Barcellini W., Ambrosetti A., Neri A., Ruggeri M., Rodeghiero F.
Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?
LEUK LYMPHOMA 2014; 55(6): 1261-1265.
________________________________________
D’Arena G., Laurenti L., Coscia M., Cortelezzi A., Chiarenza A., Pozzato G., Vigliotti M.L., Nunziata G., Fragasso A., Villa M.R., Grossi A., Selleri C., Deaglio S., La Sala A., Del Poeta G., Simeon V., Aliberti L., De Martino L., Giudice A., Musto P., De Feo V.
Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey.
LEUK LYMPHOMA 2014; 55(4): 841-847.
________________________________________
Tadmor T., Bari A., Sacchi S., Marcheselli L., Liardo E.V., Avivi I., Benyamini N., Attias D., Pozzi S., Cox M.C., Baldini L., Brugiatelli M., Federico M., Polliack A.
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era
HAEMATOL-HEMATOL J 2014; 99(1): 125-130.
________________________________________
Mauro F.R., Molica S., Laurenti L., Cortelezzi A., Carella A.M., Zaja F., Chiarenza A., Angrilli F., Nobile F., Marasca R., Musolino C., Brugiatelli M., Piciocchi A., Vignetti M., Fazi P., Gentile G., De Propris M.S., Starza I.D., Marinelli M., Chiaretti S., Del Giudice I., Nanni M., Albano F., Cuneo A., Guarini A., Foà R., GIMEMA G.
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile
LEUKEMIA RES 2014; 38(2): 198-203.
________________________________________
Iurlo A., Ubertis A., Artuso S., Bucelli C., *Radice T., Zappa M., Cattaneo D., Mari D., Cortelezzi A.
Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients
EUR J INTERN MED 2014; 25(1): 63-66.
________________________________________
Cortelezzi A., *Sciumè M., Liberati A.M., Vincenti D., Cuneo A., Reda G., Laurenti L., Zaja F., Marasca R., Chiarenza A., Gritti G., Orsucci L., Storti S., Angelucci E., Cascavilla N., Gobbi M., Mauro F.R., Morabito F., Fabris S., Piciocchi A., Vignetti M., Neri A., Rossi D. , Giannarelli D., Guarini A., Foà R.
Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.
LEUKEMIA 2014; 28(3): 642-648.
________________________________________
Tortorano A.M., Prigitano A., Esposto M.C., Arsic Arsenijevic V., Kolarovic J., Ivanovic D., Paripovic L., Klingspor L., Nordoy I., Hamal P., Arikan Akdagli S., Ossi C., Grancini A., Cavanna C., Lo Cascio G., Scarparo C., Candoni A., Caira M., Drogari Apiranthitou M., Working Group E., Boschetti C.
European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe.
EUR J CLIN MICROBIOL 2014; 33(9): 1623-1630.
________________________________________
Barcellini W.
Haemostasis and immunity: cross-talking systems?
BLOOD TRANSFUS 2014; 12(suppl 1 ): s348-s349.
________________________________________
Bari A., Tadmor T., Sacchi S., Marcheselli L., Cox C., Liardo E.V., Pozzi S., Benyamini N., Avivi I., Ferrari A., Baldini L., Falorio S., Gobbi P., Federico M., Polliack A.
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy.
BRIT J HAEMATOL 2014; 167(1): 133-136.
________________________________________
Musto P., Simeon V., Martorelli M.C., Petrucci M.T., Cascavilla N., Di Raimondo F., Caravita T., Morabito F., Offidani M., Olivieri A., Benevolo G., Mina R., Guariglia A., D’Arena G., Mansueto G., Filardi N., Nobile F., Levi A., Falcone A., Cavalli M., Pietrantuono G., Villani O., Bringhen S., Omedè P., Lerose R., Agnelli L., Todoerti K., Neri A., Boccadoro M., Palumbo A.
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
LEUKEMIA 2014; 28(1): 222-225.
________________________________________
Duarte R.F., Boumendil A., Onida F., Gabriel I., Arranz R., Arcese W., Poiré X., Kobbe G., Narni F., Cortelezzi A., Olavarria E., Schmitz N., Sureda A., Dreger P.
Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis.
J CLIN ONCOL 2014; 32(29): 3347-3348.
________________________________________
Bassan R., Spinelli O., Oldani E., Intermesoli T., Tosi M., Peruta B., Borlenghi E., Pogliani EM., Di Bona E., Cassibba V., Scattolin A.M., Romani C., Ciceri F., Cortelezzi A., Gianfaldoni G., Mattei D., Audisio E., Rambaldi A.
Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia.
BLOOD CANCER J 2014; 4(7): e225-e225.
________________________________________
Iurlo A., Gianelli U., Rapezzi D., Cattaneo D., Fermo E., *Binda F., Santambrogio E., Bucelli C., Cortelezzi A.
Imatinib and ruxolitinib association: first experience in two patients.
HAEMATOL-HEMATOL J 2014; 99(6): e76-e77.
________________________________________
Mian M., Kwee I., Rinaldi A., Ponzoni M., Bhagat G., Rossi D. , Arcaini L., Gascoyne R., Mollejo M., Baldini L., Thieblemont C., Gaidano G., Zucca E., Bertoni F.
Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas.
BRIT J HAEMATOL 2014; 164(6): 896-899.
________________________________________
Fattizzo B., *Radice T., Cattaneo D., Pomati M., Barcellini W., Iurlo A.
Three Hematologic Malignancies in the Same Patient: Chronic Lymphocytic, Followed by Chronic Myeloide Leukemia and Acute Myeloide Leukemia.
CLIN LAB 2014; 60(): 1929-1932.
________________________________________
Tripodi A., Capaccio P., Pignataro L., Chantarangkul V., Menegatti M. , Bamonti F., Clerici M., De Giuseppe R., Peyvandi F.
Thrombin generation in patients with idiopathic sudden sensorineural hearing loss.
THROMB RES 2014; 133(6): 1130-1134.
________________________________________
Fulgenzi A., De Giuseppe R., Bamonti F., Ferrero M.E.
RIVISTA CENSITA CON I.F.= 0 – Improvement of oxidative and metabolic parameters by cellfood administration in patients affected by neurodegenerative diseases on chelation treatment.
BIOMED RES INT 2014; 2014(): 281510-281
________________________________________
Rondelli T., Risitano A.M., Peffault de Latour R., Sica M., Peruzzi B., Ricci P., Barcellini W., Iori A.P., Boschetti C., Valle V., Frémeaux Bacchi V. , Angioletti M., Socie G., Luzzatto L., Notaro R.
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
HAEMATOL-HEMATOL J 2014; 99(2): 262-266.
________________________________________
Tripputi P., Bianchi P., Fermo E., Bignotto M., Zanella A.
Chromosome 7q31.1 deletion in myeloid neoplasms.
HUM PATHOL 2014; 45(2): 368-371.
________________________________________
Zanella A., Barcellini W.
Treatment of autoimmune hemolytic anemias.
HAEMATOL-HEMATOL J 2014; 99(10): 1547-1554.
________________________________________
Della Porta M.G., Alessandrino E.P., Bacigalupo A., Van Lint M.T., Malcovati L., Pascutto C., Falda M., Bernardi M., Onida F., Guidi S., Iori A.P., Cerretti R., Marenco P., Pioltelli P., Angelucci E., Oneto R., Ripamonti F., Bernasconi P., Bosi A., Cazzola M. , Rambaldi A., Gruppo Italiano Trapianto di Midollo Osseo G.
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.
BLOOD 2014; 123(15): 2333-2342.
________________________________________
Mariotti J., Maura F., Spina F., Roncari L., Dodero A., Farina L., Montefusco V., Carniti C. , Sarina B., Patriarca F., Rambaldi A., Onida F., Olivieri A., Zallio F., Corradini P.
Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.
BIOL BLOOD MARROW TR 2014; 20(6): 885-890.
________________________________________
Girmenia C., Raiola A.M., Piciocchi A., Algarotti A., Stanzani M., Cudillo L., Pecoraro C., Guidi S., Iori A.P., Montante B., Chiusolo P., Lanino E., Carella A.M., Zucchetti E., Bruno B., Irrera G., Patriarca F., Baronciani D., Musso M., Prete A., Risitano A.M., Russo D., Mordini N., Pastore D., Vacca A., Onida F., Falcioni S., Pisapia G., Milone G., Vallisa D., Olivieri A., Bonini A., Castagnola E., Sica S., Majolino I., Bosi A., Busca A., Arcese W., Bandini G., Bacigalupo A., Rambaldi A., Locasciulli A.
Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).
BIOL BLOOD MARROW TR 2014; 20(6): 872-880.
________________________________________
Morris C., De Wreede L., Scholten M., Brand R., Van Biezen A., Sureda A., Dickmeiss E., Trneny M., Apperley J., Chiusolo P., Van Imhoff G.W., Lenhoff S., Martinelli G., Hentrich M., Pabst T., Onida F., Quinn M., Kroger N., De Witte T., Ruutu T., Chronic Malignancies and Lymphoma Working Parties of E.
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide.
TRANSFUSION 2014; 54(10): 2514-2522.
________________________________________
Onida F., Brand R., Van Biezen A., Schaap M., Von dem Borne P.A., Maertens J., Beelen D.W., Carreras E., Alessandrino E.P., Volin L., Kuball J.H., Figuera A., Sierra J., Finke J., Kroger N., De Witte T., subcommitte of the EBMT – CMWP M.
Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrosp
HAEMATOL-HEMATOL J 2014; 99(10): 1582-1590.
________________________________________
Arcaini L., Vallisa D., Rattotti S., Ferretti V.V., Ferreri A.J., Bernuzzi P., Merli M., Varettoni M., Chiappella A., Ambrosetti A., Tucci A., Rusconi C., Visco C., Spina M., Cabras G., Luminari S., Tucci M., Musto P., Ladetto M., Merli F., Stelitano C., D’Arco A., Rigacci L., Levis A., Rossi D. , Spedini P., Mancuso S., Marino D., Bruno R., Baldini L., Pulsoni A.
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.
ANN ONCOL 2014; 25(7): 1404-1410.
________________________________________
Augello C., Gianelli U., Savi F., Moro A., Bonoldi E., Gambacorta M., Vaira V., Baldini L., Bosari S.
MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma.
J CLIN PATHOL 2014; 67(8): 697-701.
________________________________________
Caltagirone S., Ruggeri M., Aschero S., Gilestro M., Oddolo D., Gay F., Bringhen S., Musolino C., Baldini L., Musto P., Petrucci M.T., Gaidano G., Passera R., Bruno B., Palumbo A., Boccadoro M., Omedè P.
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.
HAEMATOL-HEMATOL J 2014; 99(10): 1611-1617.
________________________________________
Tacchetti P., Terragna C., Galli M., Zamagni E., Petrucci M.T., Pezzi A., Montefusco V., Martello M., Tosi P., Baldini L., Peccatori J., Ruggeri M., Pantani L., Lazzaro A., Elice F., Rocchi S., Gozzetti A., Cavaletti G., Palumbo A., Cavo M.
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
AM J HEMATOL 2014; 89(12): 1085-1091.
________________________________________
Bulian P., Shanafelt T.D., Fegan C., Zucchetto A., Cro L., Nuckel H., Baldini L., Kurtova A.V., Ferrajoli A., Burger J.A., Gaidano G., Del Poeta G., Pepper C., Rossi D., Gattei V.
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.
J CLIN ONCOL 2014; 32(9): 897-904.
________________________________________
Ferreri A.J., Ciceri F., Brandes A.A., Montanari M., Balzarotti M., Spina M., Ilariucci F., Zaja F., Stelitano C., Bobbio F., Corazzelli G., Baldini L., Reni M.
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.
NEUROLOGY 2014; 82(15): 1370-1373.
________________________________________
Corradini P., Vitolo U., Rambaldi A., Miceli R., Patriarca F., Gallamini A., Olivieri A., Benedetti E., Todeschini G., Rossi G., Salvi F., Bruno B., Baldini L., Ferreri A., Patti C., Tarella C., Pileri S., Dodero A.
Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma.
LEUKEMIA 2014; 28(9): 1885-1891.
________________________________________
Efficace F., Rosti G., Cottone F., Breccia M., Castagnetti F. , Iurlo A., Mandelli F., Baccarani M.
Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.
LEUKEMIA RES 2014; 38(3): 294-298.
________________________________________
Malagola M., Breccia M., Skert C., Cancelli V., Soverini S., Iacobucci I., Cattina F., Liberati A.M., Tiribelli M. , Annunziata M., Trabacchi E., de Vivo A., Castagnetti F. , Martinelli G., Fogli M., Stagno F., Pica G., Iurlo A., Pregno P., Abruzzese E., Pardini S., Bocchia M. , Russo S., Pierri I., Lunghi M., Barulli S., Merante S., Mandelli F., Alimena G., Rosti G., Baccarani M., Russo D.
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
AM J HEMATOL 2014; 89(2): 119-124.
________________________________________
Gianelli U., Bossi A., Cortinovis I., Sabattini E., Tripodo C., Boveri E., Moro A., Valli R., Ponzoni M., M Florena A., F. Orcioni G., Ascani S., Bonoldi E., Iurlo A., Gugliotta G., Franco V.
Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.
MODERN PATHOL 2014; 27(6): 814-822.
________________________________________
Randi M.L., Bertozzi I., Rumi E., Elena C., Finazzi G., Vianelli N., Polverelli N., Ruggeri M., Vannucchi A.M., Antonioli E., Lussana F., Tieghi A., Iurlo A., Elli E., Ruella M., Fabris F. , Cazzola M. , Barbui T.
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia.
AM J HEMATOL 2014; 89(3): 306-309.
________________________________________
Fraquelli M., Giunta M., Pozzi R., Rigamonti C., Della Valle S., Massironi S., Conti C.B., Aghemo A., Ronchi G., Iurlo A., Primignani M. , Conte D., Colombo M.
Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis.
J VIRAL HEPATITIS 2014; 21(2): 90-98.
________________________________________
Gianelli U., Iurlo A., Cattaneo D., Lambertenghi Deliliers G.
Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.
EXPERT REV HEMATOL 2014; 7(2): 255-264.
________________________________________
Breccia M., Luciano L., Latagliata R., Castagnetti F. , Ferrero D., Cavazzini F., Trawinska M.M., Annunziata M., Stagno F., Tiribelli M. , Binotto G., Crisà E., Musto P., Gozzini A., Cavalli L., Montefusco E., Iurlo A., Russo S., Cedrone M., Rossi A.R., Pregno P., Endri M., Spadea A., Molica M., Giglio G., Celesti F., Sorà F., Storti S., D’Addosio A., Cambrin G.R., Isidori A., Sica S., Abruzzese E., Specchia G., Rosti G., Alimena G.
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
LEUKEMIA RES 2014; 38(10): 1173-1176.
________________________________________
Lussana F., Carobbio A., Randi M.L., Elena C., Rumi E., Finazzi G., Bertozzi I., Pieri L., Ruggeri M., Palandri F. , Polverelli N., Elli E., Tieghi A., Iurlo A., Ruella M., Cazzola M. , Rambaldi A., Vannucchi A.M., Barbui T.
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.
BRIT J HAEMATOL 2014; 167(4): 541-546.
________________________________________
Colombo M. , Thummler K., Mirandola L., Garavelli S., Todoerti K., Apicella L., Lazzari E., Lancellotti M., Platonova N., Akbar M., Chiriva-Internati M., Soutar R., Neri A.
Notch signaling drives multiple myeloma induced osteoclastogenesis.
ONCOTARGET 2014; 5(21): 10393-10406.
________________________________________
Negrini M., Cutrona G., Bassi C., Fabris S., Zagatti B., Colombo M. , Ferracin M., D’Abundo L., Saccentini E., Matis S., Lionetti M., Agnelli L., Gentile M., Recchia A.G., Bossio S., Reverberi D. , Rigolin G.M., Calin G.A., Sabbioni S., Russo G., Tassone P., Morabito F., Ferrarini M., Neri A.
microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters.
CLIN CANCER RES 2014; 20(15): 4141-4153.
________________________________________
Raimondi L., Amodio N., Di Martino M.T., Altomare E., Leotta M., Caracciolo D., Gulla A., Neri A., Taverna S., D’Aquila P., Alessandro R., Giordano A., Tagliaferri P., Tassone P.
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.
ONCOTARGET 2014; 5(10): 3039-3054.
________________________________________
Leotta M., Biamonte L., Raimondi L., Ronchetti D., Martino M.T., Botta C., Leone E., Pitari M.R., Neri A., Giordano A., Tagliaferri P., Tassone P., Amodio N.
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.
J CELL PHYSIOL 2014; 229(12): 2106-2116.
________________________________________
Cottini F., Hideshima T., Xu C., Sattler M., Dori M., Agnelli L., Ten Hacken E., Bertilaccio M.T., Antonini E., Neri A., Ponzoni M., Marcatti M., Richardson P.G., Carrasco R., Kimmelman A.C., Wong K.K., Caligaris-Cappio F., Blandino G., Kuehl W.M., Anderson K.C., Tonon G.
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.
NAT MED 2014; 20(6): 599-606.
________________________________________
Gentile G., Cutrona G., Mosca L., Matis S., Fabris S., Lionetti M., Ilariucci F., Zupo S., Musolino C., Levato L., Molica S., Di Raimondo F., Vincelli I., Di Rienzo N., Pesce E.A., Angrilli F., Federico M., Neri A., Ferrarini M., Morabito F.
Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
AM J HEMATOL 2014; 89(7): 743-750.
________________________________________
Falisi E., Novella E., Visco C., Guercini N., Maura F., Giaretta I., Pomponi F., Nichele I., Finotto S., Montaldi A., Neri A., Rodeghiero F.
B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities.
HEMATOL ONCOL 2014; 32(1): 22-30.
________________________________________
Ronchetti D., Tuana G., Rinaldi A., Agnelli L., Cutrona G., Mosca L., Fabris S., Matis S., Colombo M. , Gentile M., Grazia Recchia A., Kwee I., Bertoni F., Morabito F., Ferrarini M., Neri A.
Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia.
GENE CHROMOSOME CANC 2014; 53(3): 264-273.
________________________________________
Verdelli D., Nobili L., Todoerti K., Mosca L., Fabris S., D’Anca M., Pellegrino E., Piva R., Inghirami G., Capelli C., Introna M., Baldini L., Chiaramonte R., Lombardi L., Neri A.
Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.
GENE CHROMOSOME CANC 2014; 53(2): 154-167.
________________________________________
Barcellini W., Fattizzo B., Zaninoni A., *Radice T., Nichele I., Di Bona E., Lunghi M., Tassinari C., Alfinito F., Ferrari A., Leporace A.P., Niscola P., Carpenedo M., Boschetti C., Revelli N., Villa M.A., Consonni D., Scaramucci L., De Fabritiis P., Tagariello G., Gaidano G., Rodeghiero F., Cortelezzi A., Zanella A.
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.
BLOOD 2014; 124(19): 2930-2936.
________________________________________
Martinelli I., De Stefano V., Carrobbio A., Randi M.L., Santarossa C., Rambaldi A., Finazzi M.C., Cervantes F., Arellano Rodrigo E., Rupoli S., Canafoglia L., Tieghi A., Facchini L., Betti S., Vannucchi A.M., Pieri L., Cacciola R., Cacciola E., Cortelezzi A., Iurlo A., Pogliani EM., Elli E.M., Spadea A., Barbui T.
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
AM J HEMATOL 2014; 89(11): E200-E205.
________________________________________
Iurlo A., Gianelli U., Beghini A., Spinelli O., Orofino N., Lazzaroni F., Cambiaghi S., Intermesoli T., Rambaldi A., Cortelezzi A.
Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.
ONCOTARGET 2014; 5(13): 4665-4670.
________________________________________
Visco C., Barcellini W., Maura F., Neri A., Cortelezzi A., Rodeghiero F.
Autoimmune cytopenias in chronic lymphocytic leukemia.
AM J HEMATOL 2014; 89(11): 1055-1062.
________________________________________
Hoxha M., Fabris S., Agnelli L., Bollati V., Cutrona G., Matis S., Recchia A.G., Gentile M., Cortelezzi A., Morabito F., Bertazzi P.A., Ferrarini M., Neri A.
Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia.
GENE CHROMOSOME CANC 2014; 53(7): 612-621.
